amlodipine has been researched along with Arteriosclerosis in 39 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Forty-three patients with untreated essential hypertension were randomized to receive amlodipine (n=22) or telmisartan (n=21), which were respectively administered at doses of 5 mg and 40 mg once daily in the morning for 24 weeks." | 9.12 | Renal and vascular protective effects of telmisartan in patients with essential hypertension. ( Maki, K; Morimoto, S; Sawada, K; Yano, Y, 2006) |
| "Amlodipine (a new class of calcium channel antagonist) has been shown to limit the progression of arteriosclerosis and decrease the incidence of cardiovascular events." | 7.72 | Novel anti-inflammatory actions of amlodipine in a rat model of arteriosclerosis induced by long-term inhibition of nitric oxide synthesis. ( Egashira, K; Hiasa, K; Inoue, S; Ishibashi, M; Kataoka, C; Kitamoto, S; Ni, W; Takeshita, A; Usui, M, 2004) |
| " Forty-three patients with untreated essential hypertension were randomized to receive amlodipine (n=22) or telmisartan (n=21), which were respectively administered at doses of 5 mg and 40 mg once daily in the morning for 24 weeks." | 5.12 | Renal and vascular protective effects of telmisartan in patients with essential hypertension. ( Maki, K; Morimoto, S; Sawada, K; Yano, Y, 2006) |
| "Amlodipine (a new class of calcium channel antagonist) has been shown to limit the progression of arteriosclerosis and decrease the incidence of cardiovascular events." | 3.72 | Novel anti-inflammatory actions of amlodipine in a rat model of arteriosclerosis induced by long-term inhibition of nitric oxide synthesis. ( Egashira, K; Hiasa, K; Inoue, S; Ishibashi, M; Kataoka, C; Kitamoto, S; Ni, W; Takeshita, A; Usui, M, 2004) |
| "All participants had baseline diabetic nephropathy, overt proteinuria, and hypertension and were recruited between 1996 and 1999." | 2.71 | Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy. ( Bostom, AG; Friedman, AN; Hunsicker, LG; Selhub, J, 2005) |
| "Amlodipine-lovastatin cotreatment increased sialic acid and decreased the susceptibility of LDL to oxidation more effectively than amlodipine alone." | 2.68 | Antiatherosclerotic and antiatherogenic effects of a calcium antagonist plus statin combination: amlodipine and lovastatin. ( Akhmedzhanov, NM; Orekhov, AN; Pivovarova, EM; Sobenin, IA; Tertov, VV, 1997) |
| "Amlodipine, which has membrane-remodeling properties, is emerging as an important atheroprotective drug." | 2.41 | The smooth muscle cell membrane during atherogenesis: a potential target for amlodipine in atheroprotection. ( Chen, M; Ferdinand, FD; Huang, Y; Laury-Kleintop, L; Sumner, AE; Tulenko, TN, 2001) |
| "Amlodipine has demonstrated atheroprotection in both rabbit and subhuman primate models of this disease." | 2.40 | Cholesterol, calcium and atherosclerosis: is there a role for calcium channel blockers in atheroprotection? ( Laury-Kleintop, L; Mason, RP; Tulenko, TN; Walter, MF, 1997) |
| "Amlodipine was found to normalise elevated plasma levels of oxidised LDL without reducing elevated total LDL-C levels in monkeys fed an atherogenic diet which, however, significantly suppressed atherosclerosis progression." | 2.39 | Limits of lipid-lowering therapy: the benefits of amlodipine as an anti-atherosclerotic agent. ( Kramsch, DM; Sharma, RC, 1995) |
| "Amlodipine treatment significantly reduced calcification in the lesions, whereas atorvastatin alone had no effect." | 1.32 | Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice. ( Delsing, DJ; Emeis, JJ; Havekes, LM; Jukema, JW; Princen, HM; van de Wiel, MA; van der Laarse, A, 2003) |
| "Amlodipine reduced the increase in oxidative stress by inhibiting excessive MDA production." | 1.32 | Amlodipine and glutathione cycle in hypercholesterolaemia. ( Bayindir, O; Habif, S; Mutaf, I; Ozmen, D; Parildar, Z; Turgan, N; Uysal, A, 2004) |
| "Hypercholesterolemia is associated with AT1-receptor upregulation, endothelial dysfunction, and increased NADH-dependent vascular O2*- production." | 1.30 | Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. ( Böhm, M; Bräsen, JH; Griendling, KK; Harrison, DG; Heitzer, T; Macharzina, R; Meinertz, T; Münzel, T; Nickenig, G; Schulz, E; Skatchkov, M; Stasch, JP; Warnholtz, A, 1999) |
| "Hypertension is a complex disease, the treatment of which should not only lower systolic and diastolic blood pressure but also attenuate the secondary consequences of the disease." | 1.29 | End-organ involvement and calcium antagonist therapy: animal studies. ( Nayler, WG, 1994) |
| "Concomitantly, cardiac hypertrophy was attenuated in the treated group compared with the placebo group (heart-to-body weight ratios of 4." | 1.28 | Vascular injury: mechanisms and manifestations. ( Nayler, WG, 1991) |
| "Amlodipine is a long-acting dihydropyridine calcium antagonist with vascular selectivity." | 1.28 | Vascular and myocardial effects of amlodipine: an overview. ( Gu, XH; Nayler, WG, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.56) | 18.7374 |
| 1990's | 17 (43.59) | 18.2507 |
| 2000's | 20 (51.28) | 29.6817 |
| 2010's | 1 (2.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kolos, I | 1 |
| Troitskiy, A | 1 |
| Balakhonova, T | 1 |
| Shariya, M | 1 |
| Skrypnik, D | 1 |
| Tvorogova, T | 1 |
| Deev, A | 1 |
| Boytsov, S | 1 |
| van de Poll, SW | 2 |
| Delsing, DJ | 3 |
| Jukema, JW | 3 |
| Princen, HM | 3 |
| Havekes, LM | 3 |
| Puppels, GJ | 2 |
| van der Laarse, A | 3 |
| Neumaier, J | 1 |
| Wouter Jukema, J | 1 |
| van de Wiel, MA | 1 |
| Emeis, JJ | 1 |
| Kataoka, C | 1 |
| Egashira, K | 1 |
| Ishibashi, M | 1 |
| Inoue, S | 1 |
| Ni, W | 1 |
| Hiasa, K | 1 |
| Kitamoto, S | 1 |
| Usui, M | 1 |
| Takeshita, A | 1 |
| Yamaguchi, T | 2 |
| Oishi, K | 2 |
| Uchida, M | 1 |
| Echizen, H | 2 |
| van der Hoorn, JW | 1 |
| Candido, R | 1 |
| Allen, TJ | 1 |
| Lassila, M | 1 |
| Cao, Z | 1 |
| Thallas, V | 1 |
| Cooper, ME | 1 |
| Jandeleit-Dahm, KA | 1 |
| Ida, T | 1 |
| Hiraga, M | 1 |
| Uchida, MK | 1 |
| Takai, S | 1 |
| Jin, D | 1 |
| Sakaguchi, M | 1 |
| Muramatsu, M | 1 |
| Ishii, K | 1 |
| Kirimura, K | 1 |
| Sakonjo, H | 1 |
| Miyazaki, M | 1 |
| Kahn, MB | 1 |
| Boesze-Battaglia, K | 1 |
| Stepp, DW | 1 |
| Petrov, A | 1 |
| Huang, Y | 2 |
| Mason, RP | 4 |
| Tulenko, TN | 4 |
| Mutaf, I | 1 |
| Habif, S | 1 |
| Turgan, N | 1 |
| Parildar, Z | 1 |
| Ozmen, D | 1 |
| Bayindir, O | 1 |
| Uysal, A | 1 |
| Friedman, AN | 1 |
| Hunsicker, LG | 1 |
| Selhub, J | 1 |
| Bostom, AG | 1 |
| Matsui, Y | 1 |
| Kario, K | 1 |
| Ishikawa, J | 1 |
| Hoshide, S | 1 |
| Eguchi, K | 1 |
| Shimada, K | 1 |
| Morimoto, S | 1 |
| Yano, Y | 1 |
| Maki, K | 1 |
| Sawada, K | 1 |
| Nayler, WG | 5 |
| Kramsch, DM | 1 |
| Sharma, RC | 1 |
| Chen, L | 1 |
| Haught, WH | 1 |
| Yang, B | 1 |
| Saldeen, TG | 1 |
| Parathasarathy, S | 1 |
| Mehta, JL | 1 |
| Schwartz, A | 1 |
| Eickelberg, O | 1 |
| Roth, M | 1 |
| Block, LH | 1 |
| Laury-Kleintop, L | 3 |
| Walter, MF | 2 |
| Orekhov, AN | 2 |
| Tertov, VV | 2 |
| Sobenin, IA | 1 |
| Akhmedzhanov, NM | 1 |
| Pivovarova, EM | 2 |
| Schachter, M | 1 |
| Nilsson, J | 1 |
| Brown, J | 1 |
| Khan, M | 1 |
| Warnholtz, A | 1 |
| Nickenig, G | 1 |
| Schulz, E | 1 |
| Macharzina, R | 1 |
| Bräsen, JH | 1 |
| Skatchkov, M | 1 |
| Heitzer, T | 1 |
| Stasch, JP | 1 |
| Griendling, KK | 1 |
| Harrison, DG | 1 |
| Böhm, M | 1 |
| Meinertz, T | 1 |
| Münzel, T | 1 |
| Zannad, F | 1 |
| Sumner, AE | 1 |
| Chen, M | 1 |
| Ferdinand, FD | 1 |
| Eleuteri, E | 1 |
| Fleckenstein-Grün, G | 2 |
| Frey, M | 2 |
| Thimm, F | 1 |
| Fleckenstein, A | 2 |
| Gu, XH | 2 |
| Zorn, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Preoperative Identification of the Histologically Vulnerable Plaque Using Non-invasive Imaging, Biomechanical Assessment and Baroreflex Evaluation in Patients With Severe Carotid Stenosis"[NCT05566080] | 100 participants (Actual) | Observational | 2021-03-15 | Completed | |||
| Carotid Endarterectomy Versus Optimal Medical Treatment of Asymptomatic High Grade Carotid Artery Stenosis[NCT00805311] | Phase 4 | 400 participants (Actual) | Interventional | 2009-04-30 | Terminated (stopped due to Due to the clear advantage of carotid endarterectomy) | ||
| [NCT00021918] | 0 participants | Observational | 2001-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for amlodipine and Arteriosclerosis
| Article | Year |
|---|---|
Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy.
Topics: Amlodipine; Animals; Arteriosclerosis; Atorvastatin; Calcium Channel Blockers; Combined Modality The | 2004 |
Limits of lipid-lowering therapy: the benefits of amlodipine as an anti-atherosclerotic agent.
Topics: Amlodipine; Animals; Antioxidants; Arteriosclerosis; Cholesterol, LDL; Lipoproteins, LDL | 1995 |
Pathophysiology of atherogenesis with special focus on the potential therapeutic effects of amlodipine. Introduction.
Topics: Amlodipine; Animals; Arteriosclerosis; Calcium Channel Blockers; Humans | 1997 |
Effects of amlodipine on gene expression and extracellular matrix formation in human vascular smooth muscle cells and fibroblasts: implications for vascular protection.
Topics: Amlodipine; Animals; Arteriosclerosis; Calcium Channel Blockers; Cholesterol; Extracellular Matrix; | 1997 |
Cholesterol, calcium and atherosclerosis: is there a role for calcium channel blockers in atheroprotection?
Topics: Amlodipine; Animals; Arteriosclerosis; Calcium; Calcium Channel Blockers; Calcium Channels; Cells, C | 1997 |
Vascular smooth muscle cell migration, atherosclerosis, and calcium channel blockers.
Topics: Amlodipine; Arteriosclerosis; Calcium; Calcium Channel Blockers; Calcium Channels; Cell Division; Ce | 1997 |
Pathophysiology of atherogenesis with special focus on the potential therapeutic effects of amlodipine. Summary.
Topics: Amlodipine; Animals; Arteriosclerosis; Calcium Channel Blockers; Humans | 1997 |
Atheroprotection with amlodipine: cells to lesions and the PREVENT trial. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial.
Topics: Amlodipine; Animals; Arteriosclerosis; Calcium Channel Blockers; Clinical Trials as Topic; Humans | 1999 |
The smooth muscle cell membrane during atherogenesis: a potential target for amlodipine in atheroprotection.
Topics: Amlodipine; Animals; Arteriosclerosis; Calcium; Calcium Channel Blockers; Cell Membrane; Cell Membra | 2001 |
Mechanisms of atherosclerotic plaque stabilization for a lipophilic calcium antagonist amlodipine.
Topics: Amlodipine; Arteriosclerosis; Calcium Channel Blockers; Endothelium, Vascular; Humans; Lipid Metabol | 2001 |
Protective effects of various calcium antagonists against experimental arteriosclerosis.
Topics: Amlodipine; Animals; Arteries; Arteriosclerosis; Calcium Channel Blockers; Disease Models, Animal; H | 1992 |
5 trials available for amlodipine and Arteriosclerosis
| Article | Year |
|---|---|
Modern medical treatment with or without carotid endarterectomy for severe asymptomatic carotid atherosclerosis.
Topics: Aged; Amlodipine; Arteriosclerosis; Atorvastatin; Carotid Artery Diseases; Endarterectomy, Carotid; | 2015 |
Modern medical treatment with or without carotid endarterectomy for severe asymptomatic carotid atherosclerosis.
Topics: Aged; Amlodipine; Arteriosclerosis; Atorvastatin; Carotid Artery Diseases; Endarterectomy, Carotid; | 2015 |
Modern medical treatment with or without carotid endarterectomy for severe asymptomatic carotid atherosclerosis.
Topics: Aged; Amlodipine; Arteriosclerosis; Atorvastatin; Carotid Artery Diseases; Endarterectomy, Carotid; | 2015 |
Modern medical treatment with or without carotid endarterectomy for severe asymptomatic carotid atherosclerosis.
Topics: Aged; Amlodipine; Arteriosclerosis; Atorvastatin; Carotid Artery Diseases; Endarterectomy, Carotid; | 2015 |
Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Arteriosclerosis; Biphenyl Compounds; Cardiovascular Syst | 2005 |
Renal and vascular protective effects of telmisartan in patients with essential hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis; Benzimidazoles; Benzoates; Bl | 2006 |
Antiatherosclerotic and antiatherogenic effects of a calcium antagonist plus statin combination: amlodipine and lovastatin.
Topics: Amlodipine; Anticholesteremic Agents; Aorta; Arteriosclerosis; Calcium Channel Blockers; Cell Divisi | 1997 |
[Effects of calcium antagonists on atherosclerosis progression and intima media thickness].
Topics: Amlodipine; Arteriosclerosis; Calcium Channel Blockers; Disease Progression; Echocardiography; Human | 2000 |
23 other studies available for amlodipine and Arteriosclerosis
| Article | Year |
|---|---|
Raman spectroscopic investigation of atorvastatin, amlodipine, and both on atherosclerotic plaque development in APOE*3 Leiden transgenic mice.
Topics: Amlodipine; Animals; Antihypertensive Agents; Aorta; Apolipoprotein E3; Apolipoproteins E; Arteriosc | 2002 |
[Calcium antagonist against hypertension. Arteriosclerosis controlled].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Calcium Channel Blockers; Cl | 2002 |
[Arteriosclerosis: how plaque heals].
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Arteriosclerosis; Endothelium, Vascul | 2002 |
Effects of amlodipine, atorvastatin and combination of both on advanced atherosclerotic plaque in APOE*3-Leiden transgenic mice.
Topics: Amlodipine; Animals; Anticholesteremic Agents; Aorta; Apolipoproteins E; Arteriosclerosis; Atorvasta | 2003 |
Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice.
Topics: Amlodipine; Animals; Aorta, Thoracic; Apolipoprotein E3; Apolipoproteins E; Arteriosclerosis; Atorva | 2003 |
Novel anti-inflammatory actions of amlodipine in a rat model of arteriosclerosis induced by long-term inhibition of nitric oxide synthesis.
Topics: Amlodipine; Animals; Anti-Inflammatory Agents; Arteriosclerosis; Base Sequence; Blood Pressure; Dise | 2004 |
Edaravone, a radical scavenger, may enhance or produce antiproliferative effects of fluvastatin, amlodipine, ozagrel, GF109203X and Y27632 on cultured basilar artery smooth muscle cells.
Topics: Amides; Amlodipine; Animals; Antipyrine; Arteriosclerosis; Basilar Artery; Cell Division; Cell Survi | 2003 |
Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aortic Diseas | 2004 |
[Effects of angiotensin II receptor blockers, angiotensin converting enzyme inhibitors, 3-hydroxy-3-methyl glutaryl (HMG) CoA reductase inhibitors, amlodipine and epalrestat on cultured basilar artery smooth muscle cell proliferation].
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Art | 2004 |
Comparative effects of candesartan and amlodipine in a monkey atherosclerotic model.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; Aortic | 2004 |
Influence of serum cholesterol on atherogenesis and intimal hyperplasia after angioplasty: inhibition by amlodipine.
Topics: Amlodipine; Animals; Aorta, Thoracic; Arteriosclerosis; Cholesterol, Dietary; Male; Muscle, Smooth, | 2005 |
Amlodipine and glutathione cycle in hypercholesterolaemia.
Topics: Amlodipine; Animals; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Glutathione; Hypercholeste | 2004 |
Smoking and antihypertensive medication: interaction between blood pressure reduction and arterial stiffness.
Topics: Aged; Amlodipine; Antihypertensive Agents; Arteries; Arteriosclerosis; Blood Pressure; Blood Pressur | 2005 |
End-organ involvement and calcium antagonist therapy: animal studies.
Topics: Administration, Oral; Amlodipine; Animals; Aorta, Thoracic; Arteriosclerosis; Binding Sites; Blood P | 1994 |
Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine.
Topics: Amlodipine; Animals; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Calcium Channel Block | 1997 |
The effects of antihypertensive agents on atherosclerosis-related parameters of human aorta intimal cells.
Topics: Adult; Amlodipine; Antihypertensive Agents; Aorta; Arteriosclerosis; Cell Division; Cells, Cultured; | 1998 |
Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system.
Topics: Acetylcholine; Acridines; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzym | 1999 |
[Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events].
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Arteriosclerosis; Calcium Channel Blockers; Disease Prog | 2001 |
The antiatherogenic effects of amlodipine: promise of preclinical data.
Topics: Amlodipine; Animals; Aorta; Arteriosclerosis; Calcium; Cholesterol; Dose-Response Relationship, Drug | 1992 |
Vascular injury: mechanisms and manifestations.
Topics: Amlodipine; Animals; Aorta, Thoracic; Arteriosclerosis; Calcium; Calcium Channel Blockers; Cardiomeg | 1991 |
Vascular and myocardial effects of amlodipine: an overview.
Topics: Amlodipine; Animals; Arteriosclerosis; Binding Sites; Calcium Channel Blockers; Cardiomegaly; Cerebr | 1991 |
Protecting the vasculature: an eye toward the future.
Topics: Amlodipine; Animals; Arteries; Arteriosclerosis; Blood Pressure; Calcium Channel Blockers; Cerebrova | 1990 |
Amlodipine, a new 1,4-dihydropyridine calcium antagonist with a particularly strong antihypertensive profile.
Topics: Amlodipine; Animals; Antihypertensive Agents; Arteriosclerosis; Calcium; Calcium Channel Blockers; D | 1989 |